• Nuvation Bio (NYSE:NUVB) presented nearly one additional year of follow up data from the TRUST-I and TRUST-II studies of IBTROZI (taletrectinib) at the AACR Annual Meeting 2026.
• The new data focus on long term efficacy and safety in ROS1 positive non small cell lung cancer, including both treatment naïve and previously treated patients.
• This update builds on IBTROZI's existing FDA approval and adds fresh clinical detail that has not been reflected in recent coverage of the company.

Nuvation Bio enters this clinical update with its shares at $4.4 and a 1 year return of 124.5%, alongside very large gains over 3 years, even after a 48.7% decline year to date and a 23.7% decline over the past month. For investors tracking NYSE:NUVB, this mix of strong longer term performance and recent weakness provides the backdrop for interpreting the new IBTROZI data as a fresh information input rather than just another headline.

The extended follow up from TRUST-I and TRUST-II gives investors more visibility into how IBTROZI is performing in real clinical use over time, beyond the initial approval stage. As more details emerge on durability and safety in both newly treated and previously treated patients, the market will have additional clinical evidence to consider alongside current expectations for Nuvation Bio's oncology portfolio.

Stay updated on the most important news stories for Nuvation Bio by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Nuvation Bio.

Quick Assessment

• ✅ Price vs Analyst Target: At US$4.40, the share price sits about 62% below the US$11.56 analyst price target range midpoint.
• ✅ Simply Wall St Valuation: Shares are described as trading around 89.5% below an estimated fair value, flagging a large valuation gap.
• ❌ Recent Momentum: The 30 day return of about 24% decline shows weak short term momentum into this data update.

To determine whether it may be the right time to buy, sell or hold Nuvation Bio, you can review more detailed analysis. Head to Simply Wall St's company report for the latest assessment of Nuvation Bio's Fair Value.

Key Considerations

• 📊 The extended TRUST I and TRUST II follow up strengthens the evidence base around IBTROZI in ROS1 positive NSCLC, which sits at the core of Nuvation Bio's story.
• 📊 It may be useful to watch how the market weighs this clinical update against the current US$4.40 price, the US$11.56 analyst target and the assessment that the stock trades 89.5% below estimated fair value.
• ⚠️ The company remains loss making, with a net income loss of US$204.6m and a P/E of 7.37, so funding needs and progress toward profitability are key risks to monitor alongside the trial data.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Nuvation Bio analysis. Alternatively, you can review the community page for Nuvation Bio to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.